Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Pagani O, et al. Among authors: fey mf. Breast Cancer Res Treat. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25. Breast Cancer Res Treat. 2009. PMID: 18953651 Free PMC article. Clinical Trial.
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
Gruber G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Carbone A, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Gruber G, et al. Among authors: fey mf. J Clin Oncol. 2005 Oct 1;23(28):7089-97. doi: 10.1200/JCO.2005.08.123. J Clin Oncol. 2005. PMID: 16192592 Clinical Trial.
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.
Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Collins J, Fey MF, Coates AS, Goldhirsch A; International Breast Cancer Study Group (IBCSG). Pagani O, et al. Among authors: fey mf. Breast Cancer Res Treat. 2009 Sep;117(2):319-24. doi: 10.1007/s10549-008-0282-0. Epub 2009 Jan 10. Breast Cancer Res Treat. 2009. PMID: 19137426 Free PMC article.
Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.
Crivellari D, Price K, Gelber RD, Castiglione-Gertsch M, Rudenstam CM, Lindtner J, Fey MF, Senn HJ, Coates AS, Collins J, Goldhirsch A; International Breast Cancer Study Group. Crivellari D, et al. Among authors: fey mf. J Clin Oncol. 2003 Dec 15;21(24):4517-23. doi: 10.1200/JCO.2003.03.559. J Clin Oncol. 2003. PMID: 14673038 Clinical Trial.
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam CM, Lindtner J, Erzen D, Snyder R, Collins J, Fey MF, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Colleoni M, et al. Among authors: fey mf. J Clin Oncol. 2005 Mar 1;23(7):1390-400. doi: 10.1200/JCO.2005.06.052. J Clin Oncol. 2005. PMID: 15735115 Clinical Trial.
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.
Karlsson P, Cole BF, Price KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB, Fey MF, Thürlimann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, Wallgren A. Karlsson P, et al. Among authors: fey mf. J Clin Oncol. 2007 May 20;25(15):2019-26. doi: 10.1200/JCO.2006.09.8152. Epub 2007 Apr 9. J Clin Oncol. 2007. PMID: 17420511
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.
Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. Ghielmini M, et al. Among authors: fey mf. Blood. 2004 Jun 15;103(12):4416-23. doi: 10.1182/blood-2003-10-3411. Epub 2004 Feb 19. Blood. 2004. PMID: 14976046 Free article. Clinical Trial.
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).
Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T; Swiss Group for Clinical Cancer Research. Ghielmini M, et al. Among authors: fey mf. J Clin Oncol. 2005 Feb 1;23(4):705-11. doi: 10.1200/JCO.2005.04.164. Epub 2004 Dec 14. J Clin Oncol. 2005. PMID: 15598978 Clinical Trial.
246 results